Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

por Balasa, Balaji, Yun, Rui, Belmar, Nicole A., Fox, Melvin, Chao, Debra T., Robbins, Michael D., Starling, Gary C., Rice, Audie G.
Publicado 2014

Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

por Ye, Shiming, Fox, Melvin I., Belmar, Nicole A., Sho, Mien, Chao, Debra T., Choi, Donghee, Fang, Yuni, Zhao, Vivian, Keller, Stephen F., Starling, Gary C., Culp, Patricia A.
Publicado 2017

PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis

por Woo, Jacky, Vierboom, Michel PM, Kwon, Hakju, Chao, Debra, Ye, Shiming, Li, Jianmin, Lin, Karen, Tang, Irene, Belmar, Nicole A, Hartman, Taymar, Breedveld, Elia, Vexler, Vladimir, ‘t Hart, Bert A, Law, Debbie A, Starling, Gary C
Publicado 2013